The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Plainville, Massachusetts, USA
Viral vector development and manufacturing facility
Our state-of-the-art Plainville facility delivers comprehensive sterile fill-finish and viral vector services, from process development through commercial manufacturing. With exceptional capacity and capabilities, we are fully equipped to meet market demands.
Spanning 290,000 square feet, the site adds additional North American sterile fill-finish development services, with two lines dedicated to final drug product production. It also supports the manufacturing of viral vectors for both clinical and commercial use.
Under one roof, the facility provides process and analytical development, characterization, validation, and clinical and commercial manufacturing. This integrated offering eliminates the need for costly and time-consuming facility-to-facility technology transfers.
Strategically designed for growth, the site can seamlessly accommodate future expansions up to 400,000 square feet, ensuring we continue to meet our clients’ ever-evolving needs.
Key Capabilities:
- Flexible facility designs capable of supporting both adherent and suspension (up to 2000L stirred-tank bioreactors) processes
- Bioprocess sciences lab for process/analytical development, characterization, and scale-up to 2000L
- 11 drug substance suites for viral vector production and purification
- 2 fill finish suites for final drug product production with up to 5,000 vial capacity
- Manufacturing support areas for solution prep and component prep
- Quality control labs to support on-site bioanalytical testing needs
To learn more about this location, download the site capabilities factsheet.
Helpful Resources
Webinar
Benefits of an integrated approach to gene therapy development and manufacturing
Thermo Fisher Scientific's expert will take you through the development and commercialization of viral vectors for gene therapy, so you can navigate these hurdles and deliver the project in a timely, cost-effective manner. With integrated gene therapy development and manufacturing, you can benefit more than a customized solution. It improves coordination, streamlines decision-making, and uses resources more efficiently.
Seneffe, Belgium Site
Our Seneffe facility is designed to provide comprehensive viral vector services, from process development to commercial manufacturing. This facility has over 20 years of experience in virus and viral vector manufacturing, and has been previously approved by the EMA and the FDA for commercial vaccine production.